Direkt zum Inhalt
Merck
  • Activation of cannabinoid system in anterior cingulate cortex and orbitofrontal cortex modulates cost-benefit decision making.

Activation of cannabinoid system in anterior cingulate cortex and orbitofrontal cortex modulates cost-benefit decision making.

Psychopharmacology (2014-12-23)
Abbas Khani, Mojtaba Kermani, Soghra Hesam, Abbas Haghparast, Enrike G Argandoña, Gregor Rainer
ZUSAMMENFASSUNG

Despite the evidence for altered decision making in cannabis abusers, the role of the cannabinoid system in decision-making circuits has not been studied. Here, we examined the effects of cannabinoid modulation during cost-benefit decision making in the anterior cingulate cortex (ACC) and orbitofrontal cortex (OFC), key brain areas involved in decision making. We trained different groups of rats in a delay-based and an effort-based form of cost-benefit T-maze decision-making task. During test days, the rats received local injections of either vehicle or ACEA, a cannabinoid type-1 receptor (CB1R) agonist in the ACC or OFC. We measured spontaneous locomotor activity following the same treatments and characterized CB1Rs localization on different neuronal populations within these regions using immunohistochemistry. We showed that CB1R activation in the ACC impaired decision making such that rats were less willing to invest physical effort to gain high reward. Similarly, CB1R activation in the OFC induced impulsive pattern of choice such that rats preferred small immediate rewards to large delayed rewards. Control tasks ensured that the effects were specific for differential cost-benefit tasks. Furthermore, we characterized widespread colocalizations of CB1Rs on GABAergic axonal ends but few colocalizations on glutamatergic, dopaminergic, and serotonergic neuronal ends. These results provide first direct evidence that the cannabinoid system plays a critical role in regulating cost-benefit decision making in the ACC and OFC and implicate cannabinoid modulation of synaptic ends of predominantly interneurons and to a lesser degree other neuronal populations in these two frontal regions.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Dimethylsulfoxid, Hybri-Max, sterile-filtered, BioReagent, suitable for hybridoma, ≥99.7%
Sigma-Aldrich
Dimethylsulfoxid, for molecular biology
Sigma-Aldrich
Dimethylsulfoxid, sterile-filtered, BioPerformance Certified, meets EP, USP testing specifications, suitable for hybridoma
Sigma-Aldrich
Dimethylsulfoxid, ≥99.5% (GC), suitable for plant cell culture
Sigma-Aldrich
Dimethylsulfoxid, BioUltra, for molecular biology, ≥99.5% (GC)
Sigma-Aldrich
Dimethylsulfoxid, anhydrous, ≥99.9%
Sigma-Aldrich
Dimethylsulfoxid, PCR Reagent
Sigma-Aldrich
AM251, >98% (HPLC), solid
Sigma-Aldrich
Dimethylsulfoxid, meets EP testing specifications, meets USP testing specifications
Sigma-Aldrich
DL-Tyrosin, 99%
Sigma-Aldrich
8-Octanoyloxypyren-1,3,6-Trisulfonsäure Trinatriumsalz, suitable for fluorescence, ≥90% (HPCE)
Sigma-Aldrich
Arachidonyl-2′-chloroethylamide hydrate, ≥97% (HPLC), oil